CompletedNot Applicable

Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.

South Korea36 participantsStarted 2019-04-30

Plain-language summary

Retrospective study , To analyze the clinical features and treatment outcomes in Korean blastic plasmacytoid dendritic cell neoplasm.

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patients ≥ 18 years
✓. Pathologically confirmed diagnosis by tissue or bone marrow at each center with
✓. Antigen expression of CD4 and/or CD56 coupled with at least one plasmacytoid dendritic cell-associated antigen among CD123, TCL1, CD2AP and BDCA2/CD303

✕. Acute myeloid leukemia
✕. Acute lymphoblastic leukemia
✕. Mixed phenotype acute leukemia
✕. Any type of B- or T-/NK/T-cell lymphomas
✕. Expression of lineage-specific markers for B cells (CD20, CD79a) T cells (CD3) Myeloid cells (myeloperoxidase) Monocytes (CD11c, CD163, lysozyme). CD34

Overall Survival Rate

Timeframe: from the date of the IRB approval until June 30, 2019

NCT IDNCT03974971

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-06-30